Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06465316 · ClinicalTrials.gov registry record · Phase 1

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
26
Enrollment target
14
Study locations

NCT06465316: Recruiting Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI).

NCT06465316 is a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (46% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06465316, a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
26 participants
Enrollment target
14
Study locations

Study Summary

This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.

Primary Outcome

The RP2D will be defined as the pharmacologically optimal dose of iberdomide that can be combined with teclistamab and will be selected based on all available pharmacokinetic, pharmacodynamic, target engagement, efficacy, safety and tolerability data.

Conditions Studied

Refractory Multiple Myeloma Recurrent Multiple Myeloma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • DRUG Iberdomide

Study Locations (14)

Connecticut

  • Smilow Cancer Hospital-Derby Care Center - Derby
  • Smilow Cancer Hospital Care Center - Guilford - Guilford
  • Yale University - New Haven
  • Yale-New Haven Hospital North Haven Medical Center - North Haven

Kansas

  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Moffitt Cancer Center - Tampa

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix

Minnesota

  • Mayo Clinic in Rochester - Rochester

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Virginia

  • VCU Massey Comprehensive Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2024-12-06
Est. Completion 2026-09-16
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What NCT06465316 shows while recruiting

NCT06465316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (46% lower).

The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06465316 lists 14 locations in 8 states (Connecticut, Kansas, Florida).

Frequently Asked Questions

What is clinical trial NCT06465316 about?

NCT06465316 is a clinical study titled "Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma". This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a gr...

What is the current status of trial NCT06465316?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-12-06. Estimated completion is 2026-09-16.

What conditions does trial NCT06465316 study?

This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma.

What interventions are being tested in trial NCT06465316?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Iberdomide (DRUG).

Who is sponsoring clinical trial NCT06465316?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06465316 being conducted?

This trial has 14 study locations across Arizona, Connecticut, Florida, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06465316's enrollment target sits among peer trials

26 49th of 67 higher than 19 of 67 other Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06465316

Source: ClinicalTrials.gov NCT06465316, the US trial registry maintained by the National Library of Medicine. NCT06465316 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.